HB Therapeutics Joins ICBI, Received NIH/NCI SBIR Phage I Grant

ICBI welcomes HB Therapeutic, Inc., which just received the NIH/NCI SBIR phase I grant of $300,000 for development of the company first small molecule degraders of small ubiquitin-like modifier-1 protein (SUMO1) as new anticancer drugs.

Founded by Dr. Bellail and Dr. Hao in 2015, HB Therapeutics is a biotech company for discovery and development of small molecule degraders inducing ubiquitination and degradation of oncoproteins. The first degraders of small ubiquitin-like modifier (SUMO1) protein are now in preclinical stage and several small molecule degraders of other oncoproteins are in the company pipeline for development of new classes of anticancer drugs.